Todd Morgan, MD
@wandering-gu.bsky.social
560 followers 190 following 40 posts
Jack Lapides, M.D., Research Professor and Chief of Urologic Oncology University of Michigan; Co-Director Weiser Center for Prostate Cancer
Posts Media Videos Starter Packs
Reposted by Todd Morgan, MD
wandering-gu.bsky.social
Great working with Patrick Squires and the Merck team on this MIBC RWA #gu25 @ascocancer.bsky.social
wandering-gu.bsky.social
We're hiring a PhD clinical psychologist or social worker! Looking for an energetic, passionate faculty colleague whose role would be to lead the clinical and research component of our survivorship program. Sexual health certification is desired. careers.umich.edu/job_detail/2...
careers.umich.edu
wandering-gu.bsky.social
Any recent data on screening rates?
Reposted by Todd Morgan, MD
lauracaba.bsky.social
We’ve decided on the AUA Book
club pick for 2025!

James by @percivaleverett.bsky.social

Info on time & meeting place coming soon. Support your local bookstore. 📚

See you in Las Vegas!
wandering-gu.bsky.social
So excited about this work, led by UMich Pathologist Cathryn Lapedis. We're accustomed to providing patients with reports that are uninterpretable to them, then having a subsequent decoding discussion. What happens when we make the reports understandable the first time [email protected]
jama.com
JAMA @jama.com · Jan 2
Patient-centered pathology reports improved patients' understanding of prostate biopsy results and their ability to accurately assess their cancer diagnosis and risk level, compared to standard pathology reports.

ja.ma/4a3c38z
Reposted by Todd Morgan, MD
iwashyna.bsky.social
Fascinating!

“Most study participants (44-61%) could not extract basic information—including whether they have cancer—from standard prostate cancer pathology reports but [in contrast] 93% were able to understand this diagnostic information from” patient-centered pathology reports
jama.com
JAMA @jama.com · Jan 2
Patient-centered pathology reports improved patients' understanding of prostate biopsy results and their ability to accurately assess their cancer diagnosis and risk level, compared to standard pathology reports.

ja.ma/4a3c38z
Reposted by Todd Morgan, MD
bzikmund.bsky.social
I've published literally hundreds of studies, but this one will always be special. I'm so proud to have helped Dr. Cathryn Lapedis show so convincingly how BAD current prostate biopsy pathology reports are compared to a simple patient-centered design. PLUS: my first JAMA article ever!
jama.com
JAMA @jama.com · Jan 2
Patient-centered pathology reports improved patients' understanding of prostate biopsy results and their ability to accurately assess their cancer diagnosis and risk level, compared to standard pathology reports.

ja.ma/4a3c38z
Reposted by Todd Morgan, MD
uretericbud.bsky.social
Thrilled to announce that my dear friend and colleague, Jay Simhan, MD, FACS, has been named Chair of Urology at Temple University Hospital!

I’m thrilled to partner as two departments under the Fox Chase-Temple Urologic Institute to elevate our already world-class program to even greater heights!
wandering-gu.bsky.social
Merry Christmas and Happy Hanukkah!
wandering-gu.bsky.social
Hey I was there for Coffey-Holden 2014! (Although the pic from my run looks different…)
wandering-gu.bsky.social
Found this guy in beautiful Linthicum recently @dr-coops.bsky.social
Reposted by Todd Morgan, MD
ucsfcancer.bsky.social
It is with great sadness that we mourn our cherished friend and colleague Felix Feng, MD. Felix was a distinguished physician-scientist and beloved at @ucsfhealth.bsky.social. His vision, dedication, and commitment inspired colleagues, peers everywhere, and patients. cancer.ucsf.edu/in-memoriam-...
Felix Feng, MD
wandering-gu.bsky.social
It’s great data, but the NPV isn’t necessarily all that meaningful given that only a handful those patients underwent a biopsy. Eg could have just performed a biopsy on none of those patients and get an NPV of 100%.
wandering-gu.bsky.social
You guys were a 🔥🔥 team
wandering-gu.bsky.social
Huge kudos to the NCCN for officially incorporating prostate cancer into the Genetic/Familial High-Risk Assessment Guidelines. We've come a long way!